Skip Navigation


Annals of Oncology Advance Access originally published online on September 2, 2008
Annals of Oncology 2008 19(11):1975-1976; doi:10.1093/annonc/mdn598
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/11/1975-a    most recent
mdn598v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Castro, E.
Right arrow Articles by de Álava, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castro, E.
Right arrow Articles by de Álava, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

The risk of taking the part by the whole

The first 10% of the full text of this article appears below.

Triple-negative (TN) breast cancer is a challenge in daily oncology practice, and we have read with great interest the article ‘Platinum-based chemotherapy in triple-negative breast cancer’ by Sirohi et al. [1].

Patients with TN tumors do not benefit from hormonal therapy or trastuzumab, two of the current mainstays in the systemic treatment of breast cancer. Recently, the role of a third one, anthracyclines, . . . [Full Text of this Article]

E. Castro1 and E. de Álava2

1 Department of Medical Oncology, Hospital Universitario de Salamanca
2 Molecular Pathology program, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?